S&P 500   4,221.02
DOW   33,061.57
QQQ   352.01
20 Best Healthcare Dividend Stocks to Invest in
Is Graphite the New Lithium? (Ad)
Money stored in Venmo and other payment apps could be vulnerable, financial watchdog warns
Nordstrom's Earnings Beat, A Rally In The Making
How to Invest in AI's Fast-Growing Market (Ad)
Elliott Management Says Goodyear Tire Worth At Least $21 a Share
What is the Penalty for Excess Contributions to an IRA?
How to Invest in AI's Fast-Growing Market (Ad)
Chewy.com Gets A Mouthful Of Profits: Shares Surge, More To Come
Okta, Inc: When Great Results Aren’t Good Enough 
S&P 500   4,221.02
DOW   33,061.57
QQQ   352.01
20 Best Healthcare Dividend Stocks to Invest in
Is Graphite the New Lithium? (Ad)
Money stored in Venmo and other payment apps could be vulnerable, financial watchdog warns
Nordstrom's Earnings Beat, A Rally In The Making
How to Invest in AI's Fast-Growing Market (Ad)
Elliott Management Says Goodyear Tire Worth At Least $21 a Share
What is the Penalty for Excess Contributions to an IRA?
How to Invest in AI's Fast-Growing Market (Ad)
Chewy.com Gets A Mouthful Of Profits: Shares Surge, More To Come
Okta, Inc: When Great Results Aren’t Good Enough 
S&P 500   4,221.02
DOW   33,061.57
QQQ   352.01
20 Best Healthcare Dividend Stocks to Invest in
Is Graphite the New Lithium? (Ad)
Money stored in Venmo and other payment apps could be vulnerable, financial watchdog warns
Nordstrom's Earnings Beat, A Rally In The Making
How to Invest in AI's Fast-Growing Market (Ad)
Elliott Management Says Goodyear Tire Worth At Least $21 a Share
What is the Penalty for Excess Contributions to an IRA?
How to Invest in AI's Fast-Growing Market (Ad)
Chewy.com Gets A Mouthful Of Profits: Shares Surge, More To Come
Okta, Inc: When Great Results Aren’t Good Enough 
S&P 500   4,221.02
DOW   33,061.57
QQQ   352.01
20 Best Healthcare Dividend Stocks to Invest in
Is Graphite the New Lithium? (Ad)
Money stored in Venmo and other payment apps could be vulnerable, financial watchdog warns
Nordstrom's Earnings Beat, A Rally In The Making
How to Invest in AI's Fast-Growing Market (Ad)
Elliott Management Says Goodyear Tire Worth At Least $21 a Share
What is the Penalty for Excess Contributions to an IRA?
How to Invest in AI's Fast-Growing Market (Ad)
Chewy.com Gets A Mouthful Of Profits: Shares Surge, More To Come
Okta, Inc: When Great Results Aren’t Good Enough 

Rocket Pharmaceuticals (RCKT) Stock Forecast, Price & News

$20.93
0.00 (0.00%)
(As of 06/1/2023 ET)
Compare
Today's Range
$20.36
$21.53
50-Day Range
$15.79
$22.24
52-Week Range
$9.50
$23.48
Volume
502,847 shs
Average Volume
657,391 shs
Market Capitalization
$1.68 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$51.09

Rocket Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
144.1% Upside
$51.09 Price Target
Short Interest
Bearish
10.07% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.81
Upright™ Environmental Score
News Sentiment
0.03mentions of Rocket Pharmaceuticals in the last 14 days
Based on 11 Articles This Week
Insider Trading
Selling Shares
$43,678 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($3.08) to ($2.12) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.33 out of 5 stars

Medical Sector

425th out of 1,980 stocks

Pharmaceutical Preparations Industry

183rd out of 978 stocks


RCKT stock logo

About Rocket Pharmaceuticals (NASDAQ:RCKT) Stock

Rocket Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in the development of gene therapy treatment options for rare and devastating pediatric diseases. Its multi-platform development approach applies the lentiviral vector and adeno-associated viral vector gene therapy platforms. Its clinical program is an LVV-based gene therapy for the treatment of Fanconi Anemia (FA), a difficult to treat genetic disease that leads to bone marrow failure and potentially cancer. The company was founded on July 7, 1999 and is headquartered in Cranbury, NJ.

Receive RCKT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Rocket Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

RCKT Stock News Headlines

The Real Problem With "Made in America" Lithium
Politicians love to say they support "Made in America" when it comes to manufacturing. But when it comes to lithium - the metal fueling our transition to electric vehicles - it's not that simple.
The Real Problem With "Made in America" Lithium
Politicians love to say they support "Made in America" when it comes to manufacturing. But when it comes to lithium - the metal fueling our transition to electric vehicles - it's not that simple.
See More Headlines

RCKT Price History

RCKT Company Calendar

Last Earnings
5/04/2023
Today
6/02/2023
Next Earnings (Estimated)
8/14/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:RCKT
Employees
151
Year Founded
2018

Price Target and Rating

Average Stock Price Forecast
$51.09
High Stock Price Forecast
$75.00
Low Stock Price Forecast
$34.00
Forecasted Upside/Downside
+144.1%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
12 Analysts

Profitability

Net Income
$-221,860,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$5.70 per share

Miscellaneous

Free Float
53,370,000
Market Cap
$1.68 billion
Optionable
Optionable
Beta
1.21

Social Links


Key Executives

  • Gaurav D. ShahGaurav D. Shah
    Chief Executive Officer & Director
  • Kinnari Patel
    President & Chief Operating Officer
  • John C. Militello
    Treasurer, Chief Financial & Accounting Officer
  • Mayo Pujols
    Chief Technical Officer & Executive Vice President
  • Mark White
    Chief Medical Officer













RCKT Stock - Frequently Asked Questions

Should I buy or sell Rocket Pharmaceuticals stock right now?

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Rocket Pharmaceuticals in the last year. There are currently 12 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" RCKT shares.
View RCKT analyst ratings
or view top-rated stocks.

What is Rocket Pharmaceuticals' stock price forecast for 2023?

12 analysts have issued 12-month target prices for Rocket Pharmaceuticals' stock. Their RCKT share price forecasts range from $34.00 to $75.00. On average, they anticipate the company's share price to reach $51.09 in the next twelve months. This suggests a possible upside of 144.1% from the stock's current price.
View analysts price targets for RCKT
or view top-rated stocks among Wall Street analysts.

How have RCKT shares performed in 2023?

Rocket Pharmaceuticals' stock was trading at $19.57 at the beginning of the year. Since then, RCKT shares have increased by 6.9% and is now trading at $20.93.
View the best growth stocks for 2023 here
.

When is Rocket Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, August 14th 2023.
View our RCKT earnings forecast
.

How were Rocket Pharmaceuticals' earnings last quarter?

Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) posted its quarterly earnings results on Thursday, May, 4th. The biotechnology company reported ($0.73) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.84) by $0.11. During the same quarter in the previous year, the business earned ($0.67) earnings per share.

What other stocks do shareholders of Rocket Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Rocket Pharmaceuticals investors own include Nymox Pharmaceutical (NYMX), Pfizer (PFE), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), Amarin (AMRN), Energy Transfer (ET), Micron Technology (MU), VBI Vaccines (VBIV), Vaxart (VXRT) and Alibaba Group (BABA).

What is Rocket Pharmaceuticals' stock symbol?

Rocket Pharmaceuticals trades on the NASDAQ under the ticker symbol "RCKT."

Who are Rocket Pharmaceuticals' major shareholders?

Rocket Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional shareholders include BlackRock Inc. (6.79%), Maverick Capital Ltd. (5.48%), Wellington Management Group LLP (5.11%), State Street Corp (5.00%), Westfield Capital Management Co. LP (4.02%) and Price T Rowe Associates Inc. MD (2.32%). Insiders that own company stock include Gaurav Shah, Gotham Makker, John Militello, Jonathan David Schwartz, Kinnari Patel and Rtw Investments, Lp.
View institutional ownership trends
.

How do I buy shares of Rocket Pharmaceuticals?

Shares of RCKT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Rocket Pharmaceuticals' stock price today?

One share of RCKT stock can currently be purchased for approximately $20.93.

How much money does Rocket Pharmaceuticals make?

Rocket Pharmaceuticals (NASDAQ:RCKT) has a market capitalization of $1.68 billion. The biotechnology company earns $-221,860,000.00 in net income (profit) each year or ($3.35) on an earnings per share basis.

How many employees does Rocket Pharmaceuticals have?

The company employs 151 workers across the globe.

How can I contact Rocket Pharmaceuticals?

Rocket Pharmaceuticals' mailing address is 350 FIFTH AVENUE SUITE 7530, NEW YORK NY, 10118. The official website for the company is www.rocketpharma.com. The biotechnology company can be reached via phone at (609) 659-8001, via email at investors@rocketpharma.com, or via fax at 646-224-9585.

This page (NASDAQ:RCKT) was last updated on 6/2/2023 by MarketBeat.com Staff

My Account -